EDAP slips as Q2 revenue comes in below estimates

EDAP (EDAP -5.7%) slips after its Q2 sales missed estimates earlier today.

HIFU revenue was €967K ($1.3M), compared to €1.1M($1.4) for the same period last year.

Lithotripsy division sales were €3.5M ($4.6M), compared to €5M ($6.4M) during the year ago period.

Just eight lithotripsy machines were sold during the quarter, comprised of five Sonolith i-move devices and three Sonolith Praktis devices, compared to a total of fourteen devices sold in Q212.

Comments (3)
  • pcmeehan
    , contributor
    Comments (3) | Send Message
    Why are Albatherm revenues flat outside of the US where they CE approval to sell and market since 2000?
    29 Aug 2013, 01:55 AM Reply Like
  • Big Bit
    , contributor
    Comments (2) | Send Message
    We need a new ceo!!!
    29 Aug 2013, 07:45 AM Reply Like
    , contributor
    Comments (57) | Send Message
    The whole idea of confidential info leeds me to believe there is a problem with the FDA regulatory approval process. This also indicates a problem with the board not following up with FDA request due to the lack of information needed and no one appointed to this task, a failure of the CEO or the board. In any part they may need to hire some one with experience working with and to manage FDA expectations or remove the responsible party. To have no stock holder information on this process is unacceptable and the stock price indicates the boards failure on this matter. I would like to know who is working closely with the FDA if any one. A reputable Co. would at least have a general idea of weather they expect to be approved and what requirements the FDA is looking for and a estimated time of completion of these requirements.


    Other indications of Management failure are the lack luster sales. This indicates the lack of product training or failure to compensate sales people to establish good relations with the prospective client.


    Perhaps it is time for for Edap to consider putting its self up for sale as there would seam to be a strong demand for the product in regard to the number of patients that may benefit from this technology.
    10 Sep 2013, 01:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs